Click here to BLOCK YOUR CONTENT SPACE IN OUR NEXT ISSUES |
|
|
Latest News & Press Releases |
|
|
|
|
Global Stake In The Chinese Biotech Companies Is On A Rise.
The biotechnology industry in China is coming of age as a major licencing deal has been signed between RemeGen Co Ltd and Seagen Inc, a Seattle-based company. The deal marks the biggest of all between a western company and a Chinese biotech firm.
|
|
|
| |
|
Pandemic Far From Over As New Variants Keep Us On The Edge.
Looking at the present conditions, the situation looks ripe for COVID-19 to mutate into many more variants, and the assumption that the pandemic is approaching its final stage is nothing but a thought conceived by theories that no one can prove.
|
|
|
| |
| |
|
|
|
Nasal Covid-19 Vaccine From Bharat Biotech, A Possibility.
Bharat Biotech has been granted permission by India's drug controller to execute standalone phase 3 clinical trials on the intranasal vaccine for COVID-19. Besides this, the drug regulator has also authorised the Indian biotech giant, which is based in Hyderabad...
|
|
|
| |
|
Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine Spikevax.
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced the U.S. FDA has approved the BLA for SPIKEVAX (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 18 years of age and older.
|
|
|
| |
| |
|
|
|
Britain To Finally Vaccinate 5-11 Year Old's Against COVID.
Britain has already been slow to vaccinate its 5-11 year olds, and they are now not vaccinating them as widely as the United States or Israel. NHS England has confirmed that children in the high-risk group will be the first to get the COVID-19 shot.
|
|
|
| |
|
Novavax and Israel Announce Advance Purchase Agreement for Supply of COVID-19 Vaccine.
Novavax and Israel's Ministry of Health today announced an agreement for the purchase of NVX-CoV2373, the company's recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant.
|
|
|
| | | |
| |
|
|
|
In GSK Patent Settlement, Gilead To Pay $1.25B On Biktarvy.
It doesn't come as a shock when we hear that GlaxoSmithKline and Gilead Sciences are fighting out in HIV domain for a long time, just hoping for an access to success over the other, be it new launches or even drug trials, which have been happening round the clock.
|
|
|